Tetrathiomolybdate (Generic (experimental compound))
Other Medications
Description
Tetrathiomolybdate is an experimental copper-chelating agent that has been investigated as a potential anti-cancer therapy. It works by depleting copper levels in the body, which may inhibit tumor growth and angiogenesis.
Mechanism of Action
It binds and removes copper from the body, potentially starving tumors of copper needed for angiogenesis and metastasis.
Side Effects
Neutropenia
Anemia
Nausea
Fatigue
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT00176774
Phase 2
Archived
Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma
United States
Quick Info
| Brand Name | Generic (experimental compound) |
| Category | Other Medications |
 EMA Status | Experimental |
 Spain Access | Not available |
| Clinical Trials | 1 |
Related Medications
Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.